-
05
2024
2024.05.12 -
Caliway Completes the Subject Recruitment in CBL-514 Phase 2b Study for Subcutaneous Fat Reduction
Caliway announces the completion of subject recruitment in the CBL-0205 Phase 2b study, enrolling a total of 173 subjects.
-
05
2024
2024.05.11 -
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention
Caliway is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT.
-
04
2024
2024.04.25 -
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints
CBL-0201EFP Phase 2 study demonstrated CBL-514 statistically significant efficacy in reducing cellulite severity scores at 4 and 12 weeks after treatment.
-
03
2024
Caliway Announced Orphan Drug Designation Granted to CBL-514 for the Treatment of Dercum’s Disease
CBL-514 is the first and only drug to receive both Orphan Drug Designation and Fast Track designation for Dercum’s disease treatment.
-
02
2024
2024.02.15 -
Caliway Received U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum’s Disease
CBL-514 is the first drug to receive Fast Track designation for Dercum’s disease treatment.
-
01
2024
2024.01.23 -
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
Australian Bellberry HREC has approved Caliway’s application to initiate CBL-514’s Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction.
-
01
2024
2024.01.07 -
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum’s Disease
Caliway announced that the U.S. FDA has accepted the CBL-514 IND application of CBL-0202 DD Phase 2 Study to treat Dercum’s Disease.